Triall was founded in early 2018 by a team of medical research professionals. Since then, we’ve grown into a global initiative that includes leading partners from across the clinical trial, enterprise software, blockchain, and crypto domains. Having moved into 2022 it’s time to provide you with an updated outlook of our most important objectives moving forward. In this article, we’ll delineate between our short-term and long-term roadmap. Together, these roadmaps help you understand how are short-term objectives fit within the bigger long-term vision for the Triall ecosystem.
Zoom in: our short-term roadmap
Here we provide an overview of our most recent and upcoming milestones and deliverables (see Figure 1).
Across 2021, we’ve laid the foundation for our digital ecosystem and its utility token TRL. Milestones include our initial token offering (ITO) on Ethereum, token launch on Binance Smart Chain, two CEX listings, two DEX listings, as well as the launch of various staking pools (with almost 3M TRL tokens staked).
On the clinical front, we’ve onboarded several new clinical trials into the ecosystem. These trials study the safety and efficacy of new medicines for various diseases (incl. COVID-19) and are actively using our blockchain-integrated document management solution Verial eTMF to secure and streamline their operations, all paid for in TRL. Lastly, we also integrated Verial eTMF with the LTO Network blockchain and we look forward to continuing our partnership with this pioneer in the blockchain space.
Our next objectives are all centred around the further growth of the Triall ecosystem in terms of software solutions, software clients , and major partnerships. The next section will describe our ‘bigger picture’ to help you understand where Triall is heading over the coming years.
Zoom out: our long-term roadmap
Here we describe our multi-year roadmap for the coming years, which consists of five different phases (see Figure 2). Please note that we are currently in Phase 2 Early Growth and gradually moving towards Phase 3 Build-out.
PHASE 1: ENTRY
After developing and demonstrating our first commercial product Verial eTMF, we execute the ITO of TRL. The TRL utility token plays a key role in our roadmap towards a self-sustaining digital ecosystem, in which a diverse set of stakeholders (here is an overview of all stakeholders) are incentivized to create and capture utility and value. Upon token launch, we focus on putting the fundamentals in place to stabilize and strengthen TRL’s presence in the crypto domain, pursuing additional listings and providing technology for staking and bridging.
PHASE 2: EARLY GROWTH
Having introduced TRL, we focus on retaining and growing the TRL holder base by expanding staking opportunities, investing in targeted marketing activities, and connecting to new investor audiences. In parallel, we invest in product growth by onboarding more clinical trials and by translating user feedback into user-requested product features. To prepare for the build-out and expansion of the Triall ecosystem, we grow our core team with several specialists, and we engage in business development to secure long-term strategic partnerships with established eClinical software providers, renowned research institutes, and key builders in the enterprise blockchain space.
PHASE 3: BUILD-OUT
We build out our product offering by introducing additional eClinical solutions for key clinical trial activities such as data capture, planning, oversight, and reporting. These will complement our Verial eTMF solution, and together constitute our ‘Minimum Viable Ecosystem’. We will work with leading eClinical software providers to strengthen their products using our blockchain functionalities. Moreover, we focus on developing and introducing the data structures and open-source components needed to integrate third-party applications and systems with the Triall ecosystem. We promote the utility and value of TRL by having it function as the key instrument of payment for access to ecosystem utilities.
PHASE 4: EXPANSION
We strengthen our position as a multi-sided platform for clinical trials by integrating third-party eClinical solutions and (thereby) attracting more clinical trial communities to the Triall Ecosystem. We double down on blockchain-facilitated interoperability between the different ecosystem solutions by leveraging open standards and technologies such as decentralized identifiers (DIDs) and verifiable credentials (VCs). We engage with our user and token holder communities in the design and development of targeted follow-on innovations to expedite clinical trials and drive adoption of the TRL utility token.
PHASE 5: SELF-PROPULSION
We encourage network effects by emphasizing customer acquisition and by continuing to invest in ecosystem utilities. We focus on strengthening (tokenized) incentives for creating and capturing value within our ecosystem, promoting engagement of and interaction among all different ecosystem stakeholders to effectuate a self-sustaining Triall ecosystem.
About Triall
Triall brings Web 3.0 to medical research by creating a digital ecosystem of blockchain-integrated software solutions that secure and streamline the development of new vaccines and therapeutics during clinical trials. Triall’s solutions make clinical trials tamper-resistant, and enable secure and efficient integrations between the many isolated systems and parties involved in clinical trial processes. Triall’s software is created by clinical trial professionals to ensure optimal user experience, solving actual industry pain points.
Visit the website: https://www.triall.io
Twitter: https://twitter.com/triallofficial
Telegram: https://t.me/triallcommunity
